Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Average Rating of “Moderate Buy” by Analysts

Prestige Consumer Healthcare Inc. (NYSE:PBH) has earned an average rating of “Moderate Buy” from the four research firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $85.25.

PBH has been the topic of a number of analyst reports. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a research note on Monday, December 9th. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday. Finally, DA Davidson reiterated a “buy” rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th.

Insider Buying and Selling

In related news, insider William P’pool sold 8,987 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total transaction of $735,585.95. Following the transaction, the insider now owns 20,058 shares in the company, valued at $1,641,747.30. This represents a 30.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now owns 320,952 shares of the company’s stock, valued at $26,510,635.20. The trade was a 3.28 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 38,810 shares of company stock worth $3,187,300 in the last three months. Insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. increased its stake in shares of Prestige Consumer Healthcare by 3.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock valued at $19,630,000 after buying an additional 8,533 shares during the period. Geode Capital Management LLC increased its position in Prestige Consumer Healthcare by 4.0% in the third quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock worth $95,678,000 after purchasing an additional 50,961 shares during the period. Sequoia Financial Advisors LLC raised its holdings in Prestige Consumer Healthcare by 12.9% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company’s stock worth $708,000 after purchasing an additional 1,120 shares during the last quarter. Barclays PLC lifted its position in Prestige Consumer Healthcare by 346.3% during the 3rd quarter. Barclays PLC now owns 92,444 shares of the company’s stock valued at $6,665,000 after purchasing an additional 71,730 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Prestige Consumer Healthcare by 171.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 46,931 shares of the company’s stock valued at $3,665,000 after purchasing an additional 29,649 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Trading Up 3.3 %

Prestige Consumer Healthcare stock opened at $79.19 on Tuesday. The business has a 50 day moving average price of $80.08 and a two-hundred day moving average price of $74.93. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare has a 12 month low of $60.00 and a 12 month high of $86.36. The stock has a market cap of $3.91 billion, a price-to-earnings ratio of 19.27, a price-to-earnings-growth ratio of 2.17 and a beta of 0.51.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The business had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. During the same period in the prior year, the company posted $1.07 earnings per share. Prestige Consumer Healthcare’s revenue was down .9% on a year-over-year basis. As a group, equities analysts forecast that Prestige Consumer Healthcare will post 4.46 EPS for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.